TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06464016

Intervention type: DEVICE
Intervention: Ventricular Assist Device with Berlin Heart EXCOR
Description: The Berlin Heart® EXCOR is a type of artificial heart pump that pulls blood from the ventricle and then sends that blood to the aorta or pulmonary trunc, thereby taking away extra work from the native heart. The device, which comes in several sizes, is not totally implanted inside the body.
Study: NCT06283459

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMNN-101
Description: IMNN-101 is a DNA vaccine encoding SARS-CoV-2 Omicron XBB.1.5 spike antigen. The drug product is a suspension of the DNA plasmid formulated with the facilitating agent, bis-(aza-18-crown-6)-poloxamer (Crown poloxamer, CP), and adjuvant AlPO4.
Study: NCT04986930

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT+mFOLFIRINOX
Description: Stereotactic body radiotherapy: 3500 cGy (5 fractions) mFOLFIRINOX, every 2 weeks Oxaliplatin, 85 mg/m2, intravenous, day 1 Leucovorin, 400 mg/m2, intravenous, day 1 Irinotecan, 150 mg/m2, intravenous, day 1 fluorouracil, 2,400 mg/m2, intravenous, day 1-2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFIRINOX
Description: mFOLFIRINOX, every 2 weeks Oxaliplatin, 85 mg/m2, intravenous, day 1 Leucovorin, 400 mg/m2, intravenous, day 1 Irinotecan, 150 mg/m2, intravenous, day 1 fluorouracil, 2,400 mg/m2, intravenous, day 1-2
Study: NCT05432986

Intervention type: DEVICE
Intervention: Thermal Anisotropy Measurement Device
Description: A wireless device for non-invasively assessing CSF shunt flow.
Study: NCT05581953

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omnivorous
Description: Pork-added plant-forward diet

Intervention type: OTHER
Group type: OTHER
Intervention: No meat
Description: Plant-forward no meat
Study: NCT05113433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standing frame.
Description: muscle strengthening i.e. isometrics of lower limb muscles. 5 sets/rep and 2 sets/ session.~stretching of lower limb muscles . 5sets/rep and 2 sets/session. sanding on standing frame for different time period according to group with upper limb activities lie box and blocks , cones and theraputty .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standing frame.
Description: muscle strengthening i.e. isometrics of lower limb muscles. 5 sets/rep and 2 sets/ session.~stretching of lower limb muscles . 5sets/rep and 2 sets/session. sanding on standing frame for different time period according to group with upper limb activities lie box and blocks , cones and theraputty .
Study: NCT05509569

Intervention type: DRUG
Intervention: Icatibant
Description: Icatibant, 10 to 30 mg, Subcutaneous injection
Study: NCT05357066

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous oxide gas for inhalation
Description: Administration of inhaled 50% nitrous oxide in oxygen (FiO2 0.5) will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of the placebo (oxygen-air mixture \[FiO2 ≈0.3\]), will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
Study: NCT06314477

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Description: Subjects allocated to this arm will receive continuous positive airway pressure (CPAP)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hygienic and dietary advice
Description: Subjects allocated to this arm will receive hygienic and dietary counselling
Study: NCT04775862

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: investigator choice re-challenge with anti EGFR Rx
Description: Upon second progression, patients will be enrolled into the study as per inclusion criteria and consent, and a cfDNA blood test will be drawn, and RAS status will be examined. If RAS is wildtype, then the investigator will decide whether to re-challenge with an anti EGFR antibody , or give SOC third line chemotherapy (Regorafenib or TAS-102).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: investigator choice re-challenge with anti EGFR Rx
Description: Upon second progression, patients will be enrolled into the study as per inclusion criteria and consent, and a cfDNA blood test will be drawn, and RAS status will be examined. If RAS is wildtype, then the investigator will decide whether to re-challenge with an anti EGFR antibody , or give SOC third line chemotherapy (Regorafenib or TAS-102).
Study: NCT05462444

Intervention type: OTHER
Intervention: Skin prick test
Description: Skin prick test with a standard pallete of inhalational and nutritional allergens

Intervention type: OTHER
Intervention: Skin prick test
Description: Skin prick test with a standard pallete of inhalational and nutritional allergens

Intervention type: OTHER
Intervention: Skin prick test
Description: Skin prick test with a standard pallete of inhalational and nutritional allergens
Study: NCT05556135

Intervention type: DIAGNOSTIC_TEST
Intervention: level of serun adiponectin
Description: estimation of level of serum adiponectin in NAFLD for early detection of renal impairement

Intervention type: DIAGNOSTIC_TEST
Intervention: level of serun adiponectin
Description: estimation of level of serum adiponectin in NAFLD for early detection of renal impairement
Study: NCT02839447

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic
Description: Diagnostic

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic
Description: Diagnostic
Study: NCT05465798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MC 3x3
Description: Patients allocated to this arm will receive MC 3x3, an oral supplement containing 25mg of 1,3 beta-Glucans of fungal origin (Trichoderma sp.) daily for up to three consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients allocated to this arm will receive a matching placebo similar to MC 3x3 pills used in the intervention arm. Placebos will be delivered orally every day for up to three consecutive days.
Study: NCT04801238

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LCBDE + LC
Description: Experimental group: Laparoscopic common bile duct exploration (LCBDE) + laparoscopic cholecystectomy (LC) is performed under full anaesthesia. Once the dissection has exposed the cystic a clip or ligature is placed peripherally on the cystic duct. Through an incision in the duct central to the clip or ligature a cholangiogram catheter is introduced into the cystic duct and the cholangiogram is completed.~After identification of the bile duct stones and anatomy, a cholangioscope is introduced through the duct incision into common bile duct. The stones are identified visually and removed by Dormia basket. If the stones are very large, they may be partitioned mechanically or by electrohydraulic lithotripsy. In the presence of CBDS wedged in the papilla these stones will be removed and a secondary cholangiogram will be performed. Subsequently, the cholangioscope is taken out. Then the cystic duct is divided and the gallbladder is dissected out from the liver by hook cautery and removed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERC + LC
Description: Control intervention: (First step) Endoscopic retrograde cholangiography (ERC) is routinely performed in sedation but or in full anaesthesia. ERC is performed with the patient in the supine position. The endoscope is passed down to the second part of the duodenum where the papilla is identified. Cannulation of the papilla and the common bile duct is performed with a papillotome and a guidewire. A cholangiography will confirm the presence, location and size of the CBDS and aims in further choice of extraction method. Stones can be extracted by papillotomy and by either balloon or by a basket. Additional balloon dilation of the papilla, or lithotripsy may be required. If stone extraction is incomplete or if the conditions are unclear a temporary common bile duct stent is placed which has to be removed with additional ERC after 1-2 months (Second step) laparoscopic cholecystectomy is performed after 2-14 days
Study: NCT03418649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone 50 Mg Tab
Description: 50 mg PO per day for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: PO once daily for 10 days
Study: NCT05250635

Intervention type: DEVICE
Intervention: electronic stethoscope
Description: It includes main machine and auscultation patch, which can stick on patient's body to collect and amplify breath sound.
Study: NCT00904930

Intervention type: DEVICE
Intervention: Wire Composite Splint (Dentaflex 0.45 mm)
Description: Wire-Composite-Splint: Dentaflex 0.45 mm (Dentaurum, Pforzheim, Germany) attached with Tetric flow (IvoclarVivadent, Schaadn, Liechtenstein) to the teeth

Intervention type: DEVICE
Intervention: Wire Composite Splint (Denture Strengtheners)
Description: Wire-Composite-Splint: Denture Strengtheners 0.8x1.8 mm (Dentaurum, Pforzheim, Germany) attached with Tetric flow to the teeth
Study: NCT05109039

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Description: Participants will consume 0.1g/kg body weight of creatine with 0.1g/kg body weight of maltodextrin for 42 consecutive days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will consume 0.2g/kg body weight of maltodextrin for 42 consecutive days
Study: NCT05693246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: At 10 minutes after endotracheal intubation, the Glycopyrrolate group was injected intravenously with 0.004mg/kg glycopyrrolate.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: At 10 minutes after endotracheal intubation, the Control group was intravenously injected with equal dose of normal saline.
Study: NCT05299515

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Delivered Behavioral Activation (Peer Activate)
Description: The PRS-delivered Peer Activate intervention will consist of approximately four weekly core sessions (approximately 30 minutes-1 hour) with two additional sessions to reinforce core content, and then 6 optional booster sessions to reinforce skill practice. In Peer Activate sessions, participants will learn behavioral activation and problem-solving skills to assist in their retention and persistence in methadone treatment and incorporating value-driven, substance-free, rewarding activities into their daily life.
Study: NCT04473014

Intervention type: BEHAVIORAL
Intervention: Heat Pain Paradigm
Description: A standardized heat pain paradigm will be applied. Pain threshold will be determined with the self-controlled search method starting at 32°C, with a mouse-click-induced increase of 0.1°C per click. Pain tolerance is defined as the time in seconds elapsed from the onset of the pain stimulus to a participant's withdrawal from the stimulus. Participants will be instructed to continue with the task for as long as they can and to press a button if it becomes too uncomfortable or painful. Temperature will then return to baseline. To avoid physical injury, the measurement will stop automatically at a maximum temperature of 50°C.

Intervention type: BEHAVIORAL
Intervention: Heat Pain Paradigm
Description: A standardized heat pain paradigm will be applied. Pain threshold will be determined with the self-controlled search method starting at 32°C, with a mouse-click-induced increase of 0.1°C per click. Pain tolerance is defined as the time in seconds elapsed from the onset of the pain stimulus to a participant's withdrawal from the stimulus. Participants will be instructed to continue with the task for as long as they can and to press a button if it becomes too uncomfortable or painful. Temperature will then return to baseline. To avoid physical injury, the measurement will stop automatically at a maximum temperature of 50°C.

Intervention type: BEHAVIORAL
Intervention: Heat Pain Paradigm
Description: A standardized heat pain paradigm will be applied. Pain threshold will be determined with the self-controlled search method starting at 32°C, with a mouse-click-induced increase of 0.1°C per click. Pain tolerance is defined as the time in seconds elapsed from the onset of the pain stimulus to a participant's withdrawal from the stimulus. Participants will be instructed to continue with the task for as long as they can and to press a button if it becomes too uncomfortable or painful. Temperature will then return to baseline. To avoid physical injury, the measurement will stop automatically at a maximum temperature of 50°C.
Study: NCT05098171

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Signal Switch Receptor Modified TIL
Description: Adoptive transfer of 2x10\^8-1x10\^10 autologous signal switch receptor modified TILs to patients i.v. in 30-120 minutes.
Study: NCT05056038

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral Quadratus Lumborum block
Description: Local anesthetic may spread to the T6-L1 spinal nerves and paravertebral area by spreading through the lateral QLB to the transversus abdominis plane, and posteriorly via the anterior thoracolumbar fascia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior Quadratus Lumborum Block
Description: In posterior QLB, the local anesthetic can spread on the anterior and lateral cutaneous branches of T4-L1 spinal nerves by administration of the agent to the lateral interfascial triangle.
Study: NCT06363903

Intervention type: DIAGNOSTIC_TEST
Intervention: mesh allergy test
Description: a 5 mm\^2 part of polypropylene mesh will be dissolved in 1 mL Methyl ethyl ketone (MEK), 25 microliters of this solution will be topically applied in a Finn chamber, and a reaction to the topical applicant will be assessed within 48 hours after application.

Intervention type: DIAGNOSTIC_TEST
Intervention: blood tests
Description: Blood tests for diagnosis of autoimmune diseases will be performed
Study: NCT05339750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI-based smartphone application
Description: AI-based smartphone application to record and interpret the patch test results

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Allergen patch
Description: Allergens applied to a patch which is placed on the skin on the forearm region. The patch contains 10 dime-sized disks which contain a different allergen.
Study: NCT04783779

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant of STARgraft-2 shunt in the upper arm and subsequent use for hemodialysis access
Description: After healing from the surgical procedure the graft will be routinely cannulated for hemodialysis sessions. Periodic evaluations of blood flow by ultrasound imaging will be made over the study period. Established standards of care will be followed as needed to maintain dialysis function.
Study: NCT05960331

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autonomy supported learning
Description: The ability of learners to participate in determining their own behaviour, which is the feedback schedule regarding their practice performance in this study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Practice with predetermined feedback
Description: Learners practice the motor task, while the feedback is provided according to their counterpartner
Study: NCT04723641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: functional training exercises
Description: progressive resistive functional strength training from plantigrade foot position conducted for one hour, 3 days/week. The therapist will replace the conventional physical therapy with the progressive resistive functional strength training, when this is consistent with the objectives of the strength training.
Study: NCT06188650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: After receiving DEB-BACE treatment, the enrolled patients will rest for one week and then undergo one cycle of treatment with the combination of Anlotinib and Adebelimumab. After one course of treatment, the efficacy will be re evaluated, such as CR, and the treatment with Anlotinib and Adebelimumab will continue; For PR, SD, or PD, continue to receive DEB-BACE combined with anlotinib and adebelimumab as needed, with a maximum of 4 DEB-BACE treatments, followed by continued treatment with anlotinib and adebelimumab
Study: NCT05487651

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: KUR-502
Description: KUR-502 (CD19.CAR-aNKT cells) consists of transduced allogeneic natural killer T cells (aNKT) genetically modified with additional features to enhance their anti-tumor activity against CD19+ B-cell malignancies. Following intravenous (IV) infusion, the product is expected to kill CD19+ tumor cells by direct interaction with the chimeric antigen receptor (CAR), and activation of the NKT cells to kill tumor through their innate cell killing.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: KUR-502
Description: KUR-502 (CD19.CAR-aNKT cells) consists of transduced allogeneic natural killer T cells (aNKT) genetically modified with additional features to enhance their anti-tumor activity against CD19+ B-cell malignancies. Following intravenous (IV) infusion, the product is expected to kill CD19+ tumor cells by direct interaction with the chimeric antigen receptor (CAR), and activation of the NKT cells to kill tumor through their innate cell killing.
Study: NCT06363903

Intervention type: PROCEDURE
Intervention: Mesh removal
Description: If wish for mesh removal persists, this procedure can be performed after separate informed consent (within the study), as standard practice of care.
Study: NCT05550402

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Description: Visit 1, After predosed spirometry is done, the patients will be received 4 puffs of salbutamol. 30 minutes later, if they meet the criteria of fixed airway obstruction based on ATS criteria, then they will continue to undergo serial spirometry at 1, 2, 3, and 4 hours. Then, the patients requested to be administered 4 puffs of ipratropium and do spirometry at 4.5 and 5 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Description: Visit 1, After predosed spirometry is done, the patients will be received 4 puffs of salbutamol. 30 minutes later, if they meet the criteria of fixed airway obstruction based on ATS criteria, then they will continue to undergo serial spirometry at 1, 2, 3, and 4 hours. Then, the patients requested to be administered 4 puffs of ipratropium and do spirometry at 4.5 and 5 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipratropium Bromide
Description: Visit 2, After predosed spirometry is done, the patients will be received 4 puffs of ipratropium they will continue to undergo serial spirometry at 30 minutes,1, 2, 3, and 4 hours. Then, the patients requested to be administered 4 puffs of salbutamol and do spirometry at 4.5 and 5 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipratropium Bromide
Description: Visit 2, After predosed spirometry is done, the patients will be received 4 puffs of ipratropium they will continue to undergo serial spirometry at 30 minutes,1, 2, 3, and 4 hours. Then, the patients requested to be administered 4 puffs of salbutamol and do spirometry at 4.5 and 5 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol plus Ipratropium Bromide
Description: Visit 3, After predosed spirometry is done, the patients will be received 4 puffs of a placebo, and they will do spirometry at 30 minutes, 1 and 2 hours (Placebo arm). Then, the patients requested to be administered 4 puffs of ipratropium and 4 puffs of salbutamol and do spirometry at 4.5 and 5 hours (Salbutamol plus ipratropium arm)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Visit 3, After predosed spirometry is done, the patients will be received 4 puffs of a placebo, and they will do spirometry at 30 minutes, 1 and 2 hours (Placebo arm).
Study: NCT05767346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)
Description: Aficamten (CK-3773274) tablets administered orally
Study: NCT06124937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: The intervention group will receive a 10 mg tablet of empagliflozin once a day from 3 days before surgery until discharge from the hospital.
Study: NCT05767346

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match aficamten
Description: Placebo for aficamten (CK-3773274) administered orally
Study: NCT04921254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BSG005 or placebo
Description: SAD part is a single IV infusion of ascending doses of BSG005 or placebo - a 30 minutes infusion that may be extended to 2 hours if infusion reactions occur.~The MAD part is single daily infusions of the cohort dose over 30 minutes (that may be delayed up to 2 hours in case of infusion reactions) and which will be repeated daily for 7 days. Objective is safety, tolerability and PK on day 1 and day 7 and to establish steady state plasma level.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BSG005 or placebo
Description: SAD part is a single IV infusion of ascending doses of BSG005 or placebo - a 30 minutes infusion that may be extended to 2 hours if infusion reactions occur.~The MAD part is single daily infusions of the cohort dose over 30 minutes (that may be delayed up to 2 hours in case of infusion reactions) and which will be repeated daily for 7 days. Objective is safety, tolerability and PK on day 1 and day 7 and to establish steady state plasma level.
Study: NCT06124937

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The comparator group will receive a matching placebo from 3 days before surgery until discharge from the hospital.
Study: NCT04714073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 706321
Description: BI 706321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 706321
Description: BI 706321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole
Study: NCT05767346

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg)
Description: Metoprolol succinate tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match metoprolol succinate
Description: Placebo for metoprolol succinate administered orally